Figure 7.

Protective efficacy of NILV::S_FL in a systemic prime and i.n. boost regimen in hamsters

(A) Timeline of the NILV::S_FL prime-boost or prime-target immunization regimen and challenge.

(B) Profile of serum anti-S_CoV-2 IgG response following a single (i.m.) injection or a prime (i.m.)-boost (i.n.) immunization with NILV::S_FL.

(C) Lung viral loads at 4 dpi with SARS-CoV-2 in controls or NILV::S_FL-vaccinated hamsters. Statistical significance was evaluated by a two-tailed unpaired t test; ^∗∗p < 0.01.

(D) EC₅₀ serum neutralizing titers after the boost-target regimen.

(E) Lung histological H&E analysis shown in a heatmap recapitulating the histological scores for each parameter defined in Figure S7C and determined for individuals of various groups at 4 dpi.

(F and G) Representative whole-lung section from NILV::S_FL i.m.-NILV::S_FL i.n. (F) or sham i.m.-sham i.n. (G) hamsters. See also Figure S7.